Point72 Asset Management, L.P. Adds $147M in Apellis Pharmaceuticals, Inc. ($APLS)
Key Points
- Point72 Asset Management, L.P. changed its Apellis Pharmaceuticals, Inc. ($APLS) stake by 600.0% last quarter, boosting to 4,183,918 shares worth $171.67 million.
- Wall Street's consensus rating on $APLS is Hold and an average price target of $40.92.
- $APLS last traded around $41.03.
Point72 Asset Management, L.P. increased its position in Apellis Pharmaceuticals, Inc. ($APLS) by 600.0% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,183,918 shares of Apellis Pharmaceuticals, Inc. after buying 3,586,246 shares during the quarter. Point72 Asset Management, L.P.'s holdings in Apellis Pharmaceuticals, Inc. were worth $171.67 million as of its most recent filing.
Apellis Pharmaceuticals, Inc. ($APLS) Stock
Apellis Pharmaceuticals, Inc. Earnings
Analysts Set New Price Targets
About Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts. As of May 14, 2026, Apellis Pharmaceuticals, Inc. operates as a subsidiary of Biogen Inc.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.